翰宇药业与Vitamedic Health签署司美格鲁肽对外授权协议 开拓巴西医药市场

Core Viewpoint - Hanyu Pharmaceutical has successfully entered the Brazilian market with its core product, Semaglutide, through a licensing agreement with Vitamedic Health [1] Group 1: Licensing Agreement - On January 7, Hanyu Pharmaceutical signed a licensing agreement with Brazilian pharmaceutical company Vitamedic Health for Semaglutide injection [1] - The agreement grants Vitamedic Health exclusive commercialization rights for Semaglutide-related products in Brazil [1] Group 2: Collaboration Details - The partnership will involve deep collaboration on product registration, market access, localization promotion, and long-term services [1]